Related Experiment Video
Updated: Jul 28, 2026
08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
Interleukin-10-based therapy for inflammatory bowel disease
Henri Braat1, Maikel P Peppelenbosch, Daan W Hommes
1Department of Experimental Internal Medicine, Academic Medical Center, Meiberdreef 9, 1105 AZ, Amsterdam, The Netherlands. h.braat@amc.uva.nl
Expert Opinion on Biological Therapy
|July 26, 2003
Summary
Interleukin-10 (IL-10) is crucial for intestinal tolerance in inflammatory bowel disease (IBD). While past IL-10 therapies for Crohn's disease (CD) yielded disappointing results, novel strategies show promise for future treatment.
Area of Science:
- Immunology
- Gastroenterology
- Molecular Biology
Background:
- Chronic inflammatory bowel disease (IBD), particularly Crohn's disease (CD), arises from a loss of immune tolerance to intestinal bacteria.
- Optimal immune tolerance involves pattern recognition receptors, regulatory cells, and cytokines like Interleukin-10 (IL-10).
Purpose of the Study:
- To review the characteristics and immunoregulatory properties of IL-10 in mice and humans.
- To evaluate the efficacy of IL-10 as a biological therapy for CD, summarizing clinical studies and lessons learned.
- To discuss novel IL-10 treatment strategies, including gene therapy and genetically modified bacteria.
Main Methods:
- Review of existing literature on IL-10, IBD, and Crohn's disease.
- Analysis of clinical trial data for IL-10 therapy in CD.
- Discussion of preclinical and clinical data for emerging IL-10 delivery methods.
Main Results:
- IL-10 plays a significant role in maintaining mucosal tolerance.
- Clinical trials of IL-10 for CD have shown disappointing results to date.
- Novel IL-10 therapies, including gene therapy and modified bacteria, show success in animal models.
Conclusions:
- Despite past setbacks, IL-10 remains a rational target for anti-inflammatory biological treatment in chronic IBD.
- Future IL-10 treatment should prioritize mucosal delivery and remission maintenance over induction.
- Emerging gene and bacterial therapies offer new avenues for IL-10 delivery and efficacy in IBD.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...